Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 238

  • The following terms were not found in PubMed: porsch-markus[author], janitzky-andreas[author], grube-christian[author], blaschke-simon[author], kreutze-sebastian[author], schindele-daniel[author], sulldorf-m[author], ulrich-matthias[author].
1.

Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.

Gschwend JE, Heck MM, Lehmann J, Rübben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, Stöckle M, Schnöller T, Stenzl A, Müller M, Truss M, Roth S, Liehr UB, Leißner J, Bregenzer T, Retz M.

Eur Urol. 2018 Oct 15. pii: S0302-2838(18)30737-1. doi: 10.1016/j.eururo.2018.09.047. [Epub ahead of print]

PMID:
30337060
2.

Studie zur Prädiktion von AR-V7 und CTC-Zirkulation bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom (mCRPC).

Rexer H, Hammerer P, Schostak M, König F.

Aktuelle Urol. 2018 Sep;49(5):392-393. doi: 10.1055/a-0634-7753. Epub 2018 Sep 5. German. No abstract available.

PMID:
30184595
3.

Hospital volume in ureterorenoscopic stone treatment: 99 operations per year could increase the chance of a better outcome-results of the German prospective multicentre BUSTER project.

Lebentrau S, Enzmann T, Lehsnau M, Christoph F, Schostak M, May M; BUSTER study group.

World J Urol. 2018 Aug 9. doi: 10.1007/s00345-018-2431-3. [Epub ahead of print]

PMID:
30094717
4.

Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation.

von Hardenberg J, Westhoff N, Baumunk D, Hausmann D, Martini T, Marx A, Porubsky S, Schostak M, Michel MS, Ritter M.

Urol Oncol. 2018 Sep;36(9):401.e1-401.e9. doi: 10.1016/j.urolonc.2018.05.022. Epub 2018 Aug 6.

PMID:
30093211
5.

Impact of surgeon's experience on outcome parameters following ureterorenoscopic stone removal.

Wolff I, Lebentrau S, Miernik A, Ecke T, Gilfrich C, Hoschke B, Schostak M, May M; BUSTER study group.

Urolithiasis. 2018 Jul 4. doi: 10.1007/s00240-018-1073-7. [Epub ahead of print]

PMID:
29974193
6.

[Differences between the inpatient complication rate after ureterorenoscopy and the 30-day outcome reported by the patient - results of the German prospective BUSTER study].

Wolff I, May M, Hoschke B, Gilfrich C, Peter J, Ecke T, Schostak M, Lebentrau S.

Aktuelle Urol. 2018 Jun 12. doi: 10.1055/a-0621-8705. [Epub ahead of print] German.

PMID:
29895078
7.

[Advanced Prostate Cancer Consensus Conference 2017 : Discussion of the recommendations for diagnosis and treatment of metastatic prostate cancer by a German panel of experts].

Schostak M, König F, Bögemann M, Goebell P, Hammerer P, Machtens S, Schwentner C, Thomas C, von Amsberg G, von Rundstedt FC, Heidenreich A.

Urologe A. 2018 Jul;57(7):813-820. doi: 10.1007/s00120-018-0680-9. German.

PMID:
29808368
8.

[Small renal cell carcinoma-active surveillance and ablation].

Wendler JJ, Damm R, Liehr UB, Brunner T, Pech M, Schostak M.

Urologe A. 2018 Jun;57(6):731-743. doi: 10.1007/s00120-018-0677-4. German.

PMID:
29796702
9.

Age does not matter: the relevance of immediate instillation therapy with Mitomycin C in non-muscle invasive bladder cancer.

Christoph F, Schostak M.

Transl Androl Urol. 2018 Apr;7(2):289-291. doi: 10.21037/tau.2018.03.11. No abstract available.

10.

Crosstalk between Akt signaling and cold shock proteins in mediating invasive cell phenotypes.

Hohlfeld R, Brandt S, Bernhardt A, Gorny X, Schindele D, Jandrig B, Schostak M, Isermann B, Lindquist JA, Mertens PR.

Oncotarget. 2018 Apr 10;9(27):19039-19049. doi: 10.18632/oncotarget.24886. eCollection 2018 Apr 10.

11.

Re: Letter to the editor.

Lebentrau S, Gilfrich C, Vetterlein MW, Schumacher H, Spachmann PJ, Brookman-May SD, Fritsche HM, Schostak M, Wagenlehner FM, Burger M, May M.

Int Urol Nephrol. 2018 May;50(5):875. doi: 10.1007/s11255-018-1808-y. Epub 2018 Feb 13. No abstract available.

PMID:
29441478
12.

Feasibility study of MR-guided transgluteal targeted in-bore biopsy for suspicious lesions of the prostate at 3 Tesla using a freehand approach.

Fischbach F, Wien L, Krueger S, Schnackenburg B, Baumunk D, Friebe B, Schostak M, Ricke J, Fischbach K.

Eur Radiol. 2018 Jun;28(6):2690-2699. doi: 10.1007/s00330-017-5187-z. Epub 2018 Jan 17.

PMID:
29344699
13.

[Interrater reliability and clinical impact of the Post-Ureteroscopic Lesion Scale (PULS) grading system for ureteral lesions after ureteroscopy : Results of the German prospective multicenter BUSTER project].

May M, Schönthaler M, Gilfrich C, Wolff I, Peter J, Miernik A, Fritsche HM, Burger M, Schostak M, Lebentrau S; BUSTER-Arbeitsgruppe.

Urologe A. 2018 Feb;57(2):172-180. doi: 10.1007/s00120-017-0565-3. German.

PMID:
29322235
14.

Initial Assessment of the Efficacy of Irreversible Electroporation in the Focal Treatment of Localized Renal Cell Carcinoma With Delayed-interval Kidney Tumor Resection (Irreversible Electroporation of Kidney Tumors Before Partial Nephrectomy [IRENE] Trial-An Ablate-and-Resect Pilot Study).

Wendler JJ, Pech M, Fischbach F, Jürgens J, Friebe B, Baumunk D, Porsch M, Blaschke S, Schindele D, Siedentopf S, Ricke J, Schostak M, Köllermann J, Liehr UB.

Urology. 2018 Apr;114:224-232. doi: 10.1016/j.urology.2017.12.016. Epub 2018 Jan 2.

PMID:
29305201
15.

RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease.

Christoph F, König F, Lebentrau S, Jandrig B, Krause H, Strenziok R, Schostak M.

World J Urol. 2018 Feb;36(2):187-192. doi: 10.1007/s00345-017-2145-y. Epub 2017 Dec 4.

PMID:
29204705
16.

PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.

Högner A, Krause H, Jandrig B, Kasim M, Fuller TF, Schostak M, Erbersdobler A, Patzak A, Kilic E.

Urol Oncol. 2018 Mar;36(3):94.e1-94.e14. doi: 10.1016/j.urolonc.2017.10.027. Epub 2017 Nov 21.

PMID:
29169846
17.

Prospective Multicenter Phase II Study on Focal Therapy (Hemiablation) of the Prostate with High Intensity Focused Ultrasound.

Ganzer R, Hadaschik B, Pahernik S, Koch D, Baumunk D, Kuru T, Heidenreich A, Stolzenburg JU, Schostak M, Blana A.

J Urol. 2018 Apr;199(4):983-989. doi: 10.1016/j.juro.2017.10.033. Epub 2017 Oct 26.

PMID:
29107031
18.

Non-muscle invasive bladder cancer: Are epicrises the 'Bermuda Triangle' of information transfer?

Lebentrau S, May M, Wick AK, Roiner M, Mathew M, Gilfrich C, Schostak M.

Cent European J Urol. 2017;70(3):245-251. doi: 10.5173/ceju.2017.1447. Epub 2017 Jul 14.

20.

[The recommendations of the S2k guideline for the diagnosis, therapy and metaphylaxis of urolithiasis provide a safe course of action for ureterorenoscopic stone treatment - results of the BUSTER study].

Lebentrau S, May M, Ziegler H, Werthemann P, Enzmann T, Schostak M, Porsch M; BUSTER-Studiengruppe.

Aktuelle Urol. 2018 Apr;49(2):164-170. doi: 10.1055/s-0043-116859. Epub 2017 Oct 12. German.

PMID:
29025177

Supplemental Content

Loading ...
Support Center